Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Genome Editing
- CRISPR
- Introduction
- Components of CRISPR
- Mechanism of Action
- CRISPR Gene Editing Workflow
- Advantages and Disadvantages of CRISPR Technology
- Pricing Analysis
- PESTLE Analysis
- Porter's Five Forces Analysis
- Regulatory Landscape, by Type
- Human
- Gene Drives
- Agriculture
- Animals
- Regulatory Landscape, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 3 Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Rising Incidence of Chronic Diseases
- Prevalence of Genetic Disorders
- Government and Private Funding
- Market Restraints
- Alternative Technologies
- Market Opportunities
- Increase in the Number of Applications
- Market Challenges
- Complex and Evolving Regulatory Landscape
- High Cost of CRISPR-based Therapy
Chapter 4 Emerging Technologies and Developments
- Emerging Technologies
- In Vivo Delivery of CRISPR
- Improved Cas Variants
- Artificial Intelligence
- Clinical Trials Analysis
- Clinical Trials Analysis, by Type of Study
- Clinical Trials Analysis, by Status
- Clinical Trials Analysis, by Phase
- Clinical Trials
- Patent Analysis
- Patents, by Year
- Patents, by Top Applicant
- Patents, by Top Owner
- Patents, by Jurisdiction
- Intellectual Property Disputes and Patent Issues
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Market Breakdown, by Application
- Drug Development
- Agriculture
- Diagnostics
- Other Applications
- Market Breakdown, by End User
- Biotech and Pharmaceutical Companies
- Academics and Government Research Institutes
- Contract Research Organizations
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Competitive Intelligence
- Market Analysis
- Strategic Analysis
Chapter 7 Sustainability in CRISPR Technology: An ESG Perspective
- Introduction to ESG
- Sustainability in CRISPR Technology: An ESG Perspective
- Key ESG Issues
- CRISPR Technology ESG Performance Analysis
- Environmental Performance
- Social Performance
- Governance Performance
- Concluding Remarks
List of Tables
Summary Table: Global Market for CRISPR Technology, by Application, Through 2029
Table 1: Comparison of Genome Editing Techniques
Table 2: Comparison of sgRNA Formats
Table 3: Comparison of Cas Enzymes
Table 4: Pricing Analysis of CRISPR Technology Products, by Company
Table 5: Regulatory Rating: Human Gene Editing, by Country/Region
Table 6: Regulatory Rating: Gene Drives, by Country/Region
Table 7: Regulatory Rating: Crops/Food, by Country/Region
Table 8: Regulatory Rating: Animals, by Country/Region
Table 9: Regulatory Landscape in Asia-Pacific Countries
Table 10: Regulatory Landscape in South American Countries
Table 11: Chronic Diseases: Applications of CRISPR-based Therapy
Table 12: Genetic Disease: CRISPR-based Therapy
Table 13: CRISPR Technology: Venture Funding, 2021-2024
Table 14: Clinical Trials in CRISPR Technology, by Type of Study, August 2024
Table 15: Clinical Trials in CRISPR Technology, by Status, August 2024
Table 16: Clinical Trials in CRISPR Technology, by Phase, August 2024
Table 17: Select Clinical Trials, 2024
Table 18: Patents Granted on CRISPR Technology, by Top Applicant, 2020-2023
Table 19: Patents Granted on CRISPR Technology, by Top Owner, 2020-2023
Table 20: Patents Granted on CRISPR Technology, by Jurisdiction, 2020-2023
Table 21: Global Market for CRISPR Technology, by Application, Through 2029
Table 22: CRISPR-Based Genetic Therapy: Pipeline, 2024
Table 23: Global Market for Drug Development in CRISPR Technology, by Region, Through 2029
Table 24: CRISPR-Edited Crops
Table 25: Global Market for Agriculture in CRISPR Technology, by Region, Through 2029
Table 26: CRISPR-based Diagnostics
Table 27: Global Market for Diagnostics in CRISPR Technology, by Region, Through 2029
Table 28: Global Market for Other Applications in CRISPR Technology, by Region, Through 2029
Table 29: Global Market for CRISPR Technology, by End User, Through 2029
Table 30: Biotech and Pharmaceutical Partners of CRISPR Technology Companies
Table 31: Recent Collaborations Among Biotech, Pharma and CRISPR Technology Firms, 2023-2024
Table 32: Global Market for Biotech and Pharma Companies for CRISPR Technology, by Region, Through 2029
Table 33: Global Market for Academics and Government Research Institutes for CRISPR Technology, by Region, Through 2029
Table 34: Global Market for CRO for CRISPR Technology, by Region, Through 2029
Table 35: Global Market for CRISPR Technology, by Region, Through 2029
Table 36: North American Market for CRISPR Technology, by Country, Through 2029
Table 37: European Market for CRISPR Technology, by Country, Through 2029
Table 38: Asia-Pacific Market for CRISPR Technology, by Country, Through 2029
Table 39: Leading Companies in the CRISPR Technology Market
Table 40: Small and Medium-Sized Companies in the CRISPR Technology Market
Table 41: Recent Developments in the CRISPR Technology Market, 2022-2024
Table 42: Bioethical Issues and Risks Associated with CRISPR Technology
Table 43: ESG Rankings for CRISPR Technology Companies, 2024*
Table 44: ESG: Environmental Overview
Table 45: ESG: Social Overview
Table 46: ESG: Governance Overview
Table 47: Information Sources in this Report
Table 48: Abbreviations Used in this Report
Table 49: Agilent Technologies Inc.: Company Snapshot
Table 50: Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
Table 51: Agilent Technologies Inc.: Product Portfolio
Table 52: Agilent Technologies Inc.: News/Key Developments, 2021
Table 53: Beam Therapeutics: Company Snapshot
Table 54: Beam Therapeutics: Financial Performance, FY 2022 and 2023
Table 55: Beam Therapeutics: Product Portfolio
Table 56: Beam Therapeutics: News/Key Developments, 2021-2023
Table 57: Caribou Biosciences Inc.: Company Snapshot
Table 58: Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 59: Caribou Biosciences Inc.: Product Portfolio
Table 60: Caribou Biosciences Inc.: News/Key Developments, 2021-2023
Table 61: CRISPR Therapeutics: Company Snapshot
Table 62: CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
Table 63: CRISPR Therapeutics: Product Portfolio
Table 64: CRISPR Therapeutics: News/Key Developments, 2022-2024
Table 65: Danaher Corp.: Company Snapshot
Table 66: Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 67: Danaher Corp.: Product Portfolio
Table 68: Danaher Corp.: News/Key Developments, 2021-2024
Table 69: Editas Medicine: Company Snapshot
Table 70: Editas Medicine: Financial Performance, FY 2022 and 2023
Table 71: Editas Medicine: Product Portfolio
Table 72: Editas Medicine: News/Key Developments, 2022 and 2023
Table 73: GenScript: Company Snapshot
Table 74: GenScript: Financial Performance, FY 2022 and 2023
Table 75: GenScript: Product Portfolio
Table 76: GenScript: News/Key Developments, 2021
Table 77: Intellia Therapeutics Inc.: Company Snapshot
Table 78: Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 79: Intellia Therapeutics Inc.: Product Portfolio
Table 80: Intellia Therapeutics Inc.: News/Key Developments, 2021-2023
Table 81: Lonza: Company Snapshot
Table 82: Lonza Financial Performance, FY 2022 and 2023
Table 83: Lonza: Product Portfolio
Table 84: Lonza: News/Key Developments, 2022-2024
Table 85: Merck KGaA: Company Snapshot
Table 86: Merck KGaA: Financial Performance, FY 2022 and 2023
Table 87: Merck KGaA: Product Portfolio
Table 88: Merck KGaA: News/Key Developments, 2021
Table 89: Thermo Fisher Scientific Inc.: Company Snapshot
Table 90: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 91: Thermo Fisher Scientific Inc: Product Portfolio
Table 92: Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022
List of Figures
Summary Figure: Global Market for CRISPR Technology, by Application, 2021-2029
Figure 1: CRISPR: Mechanism of Action
Figure 2: CRISPR Gene Editing: Workflow
Figure 3: Advantages and Disadvantages of CRISPR Technology
Figure 4: PESTLE Analysis - CRISPR Technology
Figure 5: Market Dynamics of CRISPR Technology
Figure 6: Estimated Numbers of All Cancer Cases, Both Sexes, 2022-2050
Figure 7: Global Estimates: People with Diabetes (20 to 79), 2021-2045
Figure 8: Emerging Trends/Technologies in the CRISPR Technology Market
Figure 9: Patents Granted on CRISPR Technology, by Year, 2020-2022
Figure 10: Global Market Shares for CRISPR Technology, by Application, 2023
Figure 11: CRISPR Technology in Drug Development
Figure 12: Uses of CRISPR in Agriculture
Figure 13: Global Market Shares for CRISPR Technology, by End User, 2023
Figure 14: Number of Scientific Publications on CRISPR, by Year, 2020-2023
Figure 15: Global Market Shares for CRISPR Technology, by Region, 2023
Figure 16: North American Market Shares of CRISPR Technology, by Country, 2023
Figure 17: U.S. Market for CRISPR Technology, 2021-2029
Figure 18: Canadian Market for CRISPR Technology, 2021-2029
Figure 19: European Market Shares of CRISPR Technology, by Country, 2023
Figure 20: German Market for CRISPR Technology, 2021-2029
Figure 21: U.K. Market for CRISPR Technology, 2021-2029
Figure 22: French Market for CRISPR Technology, 2021-2029
Figure 23: Rest of the European Market for CRISPR Technology, 2021-2029
Figure 24: Asia-Pacific Market Shares of CRISPR Technology, by Country, 2023
Figure 25: Chinese Market for CRISPR Technology, 2021-2029
Figure 26: Japanese Market for CRISPR Technology, 2021-2029
Figure 27: Indian Market for CRISPR Technology, 2021-2029
Figure 28: Rest of Asia-Pacific Market for CRISPR Technology, 2021-2029
Figure 29: RoW Market for CRISPR Technology, 2021-2029
Figure 30: Pillars of ESG
Figure 31: Advantages of ESG for Companies
Figure 32: Methodology Used in the CRISPR Technology Market
Figure 33: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
Figure 34: Agilent Technologies Inc.: Revenue Share, by Region, FY 2023
Figure 35: Caribou Biosciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 36: Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 37: Danaher Corp.: Market Share, by Business Unit, FY 2023
Figure 38: Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 39: GenScript: Revenue Share, by Business Unit, FY 2023
Figure 40: GenScript: Revenue Share, by Country/Region, FY 2023
Figure 41: Lonza: Revenue Share, by Business Unit, FY 2023
Figure 42: Lonza: Revenue Share, by Country/Region, FY 2023
Figure 43: Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 44: Merck KGaA: Revenue Share, by Region, FY 2023
Figure 45: Thermo Fisher Scientific Inc.: Market Share, by Business Unit, FY 2023
Figure 46: Thermo Fisher Scientific Inc.: Revenue Share, by Region, FY 2023
